Pharmacokinetic, efficacy, and safety considerations for the use of antifungal drugs in the neonatal population

References

• Benjamin DK Jr., Stoll BJ, Gantz MG, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics. 2010;126(4):e865–e873.
   Google Scholar
• Clerihew L, Lamagni TL, Brocklehurst P. et al. Candida parapsilosis infection in very low birthweight infants. Arch Dis Childhood Fetal Neonatal Ed. 2007;92(2):F127–F129.
   Google Scholar
• Benjamin DK Jr., Ross K, McKinney RE Jr., et al. When to suspect fungal infection in neonates: A clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics. 2000;106(4):712–718.
   Google Scholar
• Benjamin DK Jr., Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117(1):84–92.
   Google Scholar
• Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995–2004. Pediatrics. 2006;117(5):1680–1687.
   Google Scholar
• Healy CM, Baker CJ, Zaccaria E, et al. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr. 2005;147(2):166–171.
   Google Scholar
• Healy CM, Campbell JR, Zaccaria E, et al. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics. 2008;121(4):703–710.
   Google Scholar
• Manzoni P, Leonessa M, Galletto P, et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J. 2008;27(8):731–737.
   Google Scholar
• Brian Smith P, Steinbach WJ, Benjamin DK Jr. Invasive Candida infections in the neonate. Drug Resist Updat. 2005;8(3):147–162.
   Google Scholar
• Hundalani S, Pammi M. Invasive fungal infections in newborns and current management strategies. Expert Rev Anti Infect Ther. 2013;11(7):709–721.
   Google Scholar
• Smith PB, Steinbach WJ, Benjamin DK Jr. Neonatal candidiasis. Infect Dis Clin North Am. 2005 Sep;19(3):603–615.
   Google Scholar
• Benjamin DK, DeLong E, Cotten CM, et al. Mortality following blood culture in premature infants: increased with gram-negative bacteremia and candidemia, but not gram-positive bacteremia. J Perinatol. 2004;24(3):175–180.
   Google Scholar
• Benjamin DK Jr., Poole C, Steinbach WJ, et al. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics. 2003;112(3 Pt 1):634–640.
   Google Scholar
• Fernandez M, Moylett EH, Noyola DE, et al. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis. 2000;31(2):458–463.
   Google Scholar
• Cohen-Wolkowiez M, Smith PB, Mangum B, et al. Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures. J Perinatol. 2007;27(2):97–100.
   Google Scholar
• Watt K, Benjamin DK, Cohen-Wolkowiez M. Pharmacokinetics of antifungal agents in children. Early Hum Dev. 2011;87(SUPPL):S61–S65.
   Google Scholar
• Cohen-Wolkowiez M, Moran C, Benjamin DK, et al. Pediatric antifungal agents [Review]. Curr Opin Infect Dis. 2009;22(6):553–558.
   Google Scholar
• X-Gen Pharmaceuticals, Inc. Amphotericin B deoxycholate [package insert]. National Institute of Health website. 2009 December [cited 2020 Mar 18]. Available from: https://aidsinfo.nih.gov/drugs/6/amphotericin-b/117/professional
   Google Scholar
• Sarosi GA, Amphotericin B. Still the ‘gold standard’ for antifungal therapy. Postgrad Med. 1990;88(1):151–166.
   Google Scholar
• Gallis HA, Drew RH, Pickard WW, et al. 30 years of clinical experience. Rev Infect Dis. 1990 Mar–Apr;12(2):308–329.
   Google Scholar
• Jeon GW, Koo SH, Lee JH, et al. A comparison of AmBisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants. Yonsei Med J. 2007;48(4):619–626.
   Google Scholar
• Rogers PD, Krysan DJ. Antifungal Agents. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics. New York, NY: McGraw-Hill Education; 2017. p. 13e.
   Google Scholar
• Janknegt R, de Marie S, Bakker-Woudenberg IA, et al. Liposomal and lipid formulations of amphotericin B clinical pharmacokinetics. Clin Pharmacokinet. 1992;23(4):279–291.
   Google Scholar
• Koren G, Lau A, Klein J, et al. Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr. 1988;113(3):559–563.
   Google Scholar
• Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr. 1990;116(5):791–797.
   Google Scholar
• Luna B, Drew RH, Perfect JR. Agents for treatment of invasive fungal infections. Otolaryngol Clin North Am. 2000 Apr;33(2):277–299.
   Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 2016;62(4):e1–e50.
   Google Scholar
• Le J, Adler-Shohet FC, Nguyen C, et al. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J. 2009;28(12):1061–1063.
   Google Scholar
• Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother. 2003;52(4):663–667.
   Google Scholar
• Gilead Sciences, Inc. Liposomal amphotericin B [package insert]. U.S. Food and Drug Administration website; 2012Mar [cited 2020 Mar 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf
   Google Scholar
• Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 2002;46(6):1773–1780.
   Google Scholar
• Adler-Moore J. Development, characterization and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res. 1993;3(3):429–450.
   Google Scholar
• Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001 Dec;45(12):3487–3496.
   Google Scholar
• Hong Y, Shaw PJ, Nath CE, et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother. 2006 Mar;50(3):935–942.
   Google Scholar
• Kotwani RN, Gokhale PC, Bodhe PV, et al. A comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates [article]. Int J Pharm. 2002;238(1–2):11–15.
   Google Scholar
• Juster-Reicher A, Flidel-Rimon O, Amitay M, et al. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis. 2003;22(10):603–607.
   Google Scholar
• Scarcella A, Pasquariello MB, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J. 1998;17(2):146–148.
   Google Scholar
• Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182(1):274–282.
   Google Scholar
• Pediatrics A. Candidiasis. In: Kimberlin DW, Brady MT, Jackson MA, et al., editors. Red book: 2018 report of the committee on infectious diseases. 31 ed. Ithaca, IL: American Academy of Pediatrics; 2018. p. 266–267.
   Google Scholar
• Bennet JE. Flucytosine. Ann Intern Med. 1977;86(3):319–321.
   Google Scholar
• Valeant Pharmaceuticals International. Flucytosine [package insert]. U.S. Food and Drug Administration website; 2006 May [cited 2020 Mar 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017001s027lbl.pdf
   Google Scholar
• Tassel D, Madoff MA. Treatment of Candida sepsis and cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent. JAMA. 1968;206(4):830–832.
   Google Scholar
• Polak A, Scholer HJ. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy. 1975;21(3–4):113–130.
   Google Scholar
• Medoff G, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N Engl J Med. 1980;302(3):145–155.
   Google Scholar
• Armstrong D, Schmitt HJ. Older drugs. In: Ryley J, editor. Chemotherapy for fungal diseases. Berlin: Springer; 1990. p. 439–454.
   Google Scholar
• Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther. 1978;24(3):333–342.
   Google Scholar
• Schönebeck J, Polak A, Fernex M, et al. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy. 1973;18(6):321–336.
   Google Scholar
• Vermes A, van Der Sijs H, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy. 2000 Mar-Apr;46(2):86–94.
   Google Scholar
• Soltani M, Tobin CM, Bowker KE, et al. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents. 2006;28(6):574–577.
   Google Scholar
• Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979;301(3):126–131.
   Google Scholar
• Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis. 1992;15(6):1003–1018.
   Google Scholar
• Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272–279.
   Google Scholar
• Stockmann C, Constance JE, Roberts JK, et al. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Clin Pharmacokinet. 2014;53(5):429–454.
   Google Scholar
• Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27(1):68–88.
   Google Scholar
• Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011;86(8):805–817.
   Google Scholar
• Pfizer. Fluconazole [package insert]. U.S. Food and Drug Administration website; 2011 May [cited 2020 Mar 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf
   Google Scholar
• Pfizer. Fluconazole [product information]. European Medicines Agency website [cited 2020 May 15]. Available from: https://www.ema.europa.eu/en/documents/referral/diflucan-article-30-referral-annex-iii_en.pdf
   Google Scholar
• Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol. 2004;42(4):1519–1527.
   Google Scholar
• Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990 Mar–Apr;12(Suppl 3):S318–S326.
   Google Scholar
• Nahata MC, KB T, RW F. Pharmacokinetics of fluconazole in young infants. Eur J Drug Metab Pharmacokinet. 1999 Apr–Jun;24(2):155–157.
   Google Scholar
• Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999;12(1):40–79.
   Google Scholar
• Wildfeuer A, Laufen H, Schmalreck AF, et al. Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. Mycoses. 1997;40(7–8):259–265.
   Google Scholar
• Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis. 1994 Apr;13(4):325–329.
   Google Scholar
• Berl T, Wilner KD, Gardner M, et al. Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol. 1995;6(2):242–247.
   Google Scholar
• Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008 Nov;52(11):4043–4049.
   Google Scholar
• Saxén H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther. 1993;54(3):269–277.
   Google Scholar
• Wenzl TG, Schefels J, Hornchen H, et al. Pharmacokinetics of oral fluconazole in premature infants. Eur J Pediatr. 1998 Aug;157(8):661–662.
   Google Scholar
• Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am. 2006;20(3):679–697.
   Google Scholar
• Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006;19(2):435–447.
   Google Scholar
• Wade KC, Benjamin DK Jr., Kaufman DA, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J. 2009;28(8):717–723.
   Google Scholar
• Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet. 1997;33(1):52–77.
   Google Scholar
• Piper L, Smith PB, Hornik CP, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J. 2011;30(5):375–378.
   Google Scholar
• Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356(24):2483–2495.
   Google Scholar
• Benjamin DK Jr., Hudak ML, Duara S, et al. Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. JAMA. 2014;311(17):1742–1749.
   Google Scholar
• Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345(23):1660–1666.
   Google Scholar
• Parikh TB, Nanavati RN, Patankar CV, et al. Fluconazole prophylaxis against fungal colonization and invasive fungal infection in very low birth weight infants. Indian Pediatr. 2007;44(11):830–837.
   Google Scholar
• Kaufman D, Boyle R, Hazen KC, et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr. 2005;147(2):172–179.
   Google Scholar
• Kicklighter SD, Springer SC, Cox T, et al. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics. 2001;107(2):293–298.
   Google Scholar
• Pfizer. Voriconazole [package insert]. U.S. Food and Drug Administration website; 2010 June [cited 2020 Mar 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021266s032lbl.pdf
   Google Scholar
• Accord Healthcare S.L.U. Voriconazole [product information]. European Medicines Agency website; 2018 February [cited 2020 May 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/voriconazole-accord-epar-product-information_en.pdf
   Google Scholar
• Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother. 2000;34(9):1032–1043.
   Google Scholar
• Celik IH, Demirel G, Oguz SS, et al. Compassionate use of voriconazole in newborn infants diagnosed with severe invasive fungal sepsis. Eur Rev Med Pharmacol Sci. 2013;17(6):729–734.
   Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630–637.
   Google Scholar
• Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48(6):2166–2172.
   Google Scholar
• Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50(1):27–36.
   Google Scholar
• Spriet I, Cosaert K, Renard M, et al. Voriconazole plasma levels in children are highly variable. Eur J Clin Microbiol Infect Dis. 2011;30(2):283–287.
   Google Scholar
• Shima H, Miharu M, Osumi T, et al. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer. 2010;54(7):1050–1052.
   Google Scholar
• RJM B, JWM VDL, Verweij PE, et al. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J. 2011;30(6):533–534.
   Google Scholar
• Doby EH, Benjamin DK Jr., Blaschke AJ, et al. Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J. 2012;31(6):632–635.
   Google Scholar
• Pasqualotto AC, Shah M, Wynn R, et al. Voriconazole plasma monitoring. Arch Dis Child. 2008;93(7):578–581.
   Google Scholar
• Purkins L, Wood N, Greenhalgh K, et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003;56(Suppl1):10–16.
   Google Scholar
• Michael C, Bierbach U, Frenzel K, et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother. 2010;54(8):3225–3232.
   Google Scholar
• Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54(10):4116–4123.
   Google Scholar
• Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53(3):935–944.
   Google Scholar
• Kohli V, Taneja V, Sachdev P, et al. Voriconazole in newborns. Indian Pediatr. 2008;45(3):236–238.
   Google Scholar
• Santos RP, Sánchez PJ, Mejias A, et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J. 2007;26(4):364–366.
   Google Scholar
• Frankenbusch K, Eifinger F, Kribs A, et al. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight. J Perinatol. 2006;26(8):511–514.
   Google Scholar
• KaM M, Maples HD, Stowe CD, et al. Intravenous voriconazole therapy in a preterm infant. Pharmacotherapy. 2005;25(6):893–898.
   Google Scholar
• Soler-Palacín P, Frick MA, Martín-Nalda A, et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother. 2012;67(3):700–706.
   Google Scholar
• Boyd AE, Modi S, Howard SJ, et al. Adverse reactions to voriconazole. Clin Infect Dis. 2004;39(8):1241–1244. .
   Google Scholar
• Imhof A, Schaer DJ, Schanz U, et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006;136(45–46):739–742. .
   Google Scholar
• Merck. Posaconazole [package insert]. U.S. Food and Drug Administration website; 2015 November [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf
   Google Scholar
• Accord Healthcare Limited. Posaconazole [product information]. European Medicines Agency website [cited 2020 May 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/posaconazole-accord-epar-product-information_en.pdf
   Google Scholar
• Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003 Sep;47(9):2788–2795. .
   Google Scholar
• Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther. 2007 Sep;29(9):1862–1886.
   Google Scholar
• Chen SCA, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71(1):11–41.
   Google Scholar
• Simitsopoulou M, Peshkova P, Tasina E, et al. Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates. Antimicrob Agents Chemother. 2013;57(6):2562–2570. .
   Google Scholar
• Pieroni KP, Nespor C, Poole RL, et al. Echinocandin and ethanol lock therapy treatment of fungal catheter infections. Pediatr Infect Dis J. 2013;32(3):289–291. .
   Google Scholar
• Astellas Pharma, Inc. Micafungin [package insert]. U.S. Food and Drug Administration website; 2011 June [cited 2020 Mar 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021506s011s012lbl.pdf
   Google Scholar
• European Medicines Agency 1995–2019 [updated October 9th 2019;February 26th. 2020. [cited 2020 Mar 18]. ccx Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000734/human_med_000911.jsp
   Google Scholar
• Groll AH, Mickiene D, Petraitis V, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother. 2001;45(12):3322–3327. .
   Google Scholar
• Yamada N, Kumada K, Kishino S, et al. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J Infect Chemother. 2011;17(5):731–734. .
   Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142–1151. .
   Google Scholar
• Hirata K, Aoyama T, Matsumoto Y, et al. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi. 2007;127(5):897–901.
   Google Scholar
• Maseda E, Grau S, Villagran M-J, et al. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. J Antimicrob Chemother. 2014;69(6):1624–1632.
   Google Scholar
• Heresi GP, Gerstmann DR, Reed MD, et al., The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25(12): 1110–1115.
   Google Scholar
• Natarajan G, Lulic-Botica M, Aranda JV. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. J Perinatol. 2009;29(11):738–743.
   Google Scholar
• Smith PB, Walsh TJ, Hope W, et al., Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28(5): 412–415.
   Google Scholar
• Kawada M, Fukuoka N, Kondo M, et al., Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. Pediatr Infect Dis J. 2009;28(9): 840–842.
   Google Scholar
• Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010 Jun;54(6):2633–2637.
   Google Scholar
• Benjamin DK Jr., Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010 Jan;87(1):93–99.
   Google Scholar
• Hoffman JA, Walsh TJ. Echinocandins in children. Pediatr Infect Dis J. 2011;30(6):508–509.
   Google Scholar
• Yanni SB, Smith PB, Benjamin DK Jr., et al. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharm Drug Dispos. 2011 May;32(4):222–232.
   Google Scholar
• Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49(8):3317–3324.
   Google Scholar
• Autmizguine J, Hornik CP, Benjamin DK Jr., et al. Pharmacokinetics and safety of micafungin in infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J. 2016;35(11):1204–1210.
   Google Scholar
• Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother. 2007;51(10):3714–3719.
   Google Scholar
• Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008 Jan 1;197(1):163–171.
   Google Scholar
• Hope WW, Castagnola E, Groll AH, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012 Dec;18(Suppl 7):38–52.
   Google Scholar
• King KY, Edwards MS, Word BM. Hepatitis associated with micafungin use in a preterm infant. J Perinatol. 2009;29(4):320–322.
   Google Scholar
• Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27(9):820–826.
   Google Scholar
• Manzoni P, Wu C, Tweddle L, et al. Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials. Pediatr Infect Dis J. 2014 Nov;33(11):e291–8.
   Google Scholar
• Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother. 2008;61(1):17–25.
   Google Scholar
• Andes D. Optimizing antifungal choice and administration. Curr Med Res Opin. 2013;29(Suppl 4):13–18.
   Google Scholar
• Pfaller MA, Diekema DJ, Boyken L, et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother. 2005;49(11):4795–4797.
   Google Scholar
• Vazquez JA, Schranz JA, Clark K, et al. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr. 2008;48(3):304–309.
   Google Scholar
• Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472–2482.
   Google Scholar
• Pfizer. Anidulafungin [package insert]. U.S. Food and Drug Administration website; 2012 [cited 2020 Mar 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf
   Google Scholar
• Pfizer Manufacturing Belgium NV. Anidulafungin [product information]. European Medicines Agency website; 2017 August [cited 2020 May 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/ecalta-epar-product-information_en.pdf
   Google Scholar
• Damle B, Stogniew M, Dowell J. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother. 2008;52(7):2673–2676.
   Google Scholar
• Benjamin DK Jr., Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006;50(2):632–638.
   Google Scholar
• Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004;44(6):590–598.
   Google Scholar
• Dowell JA, Stogniew M, Krause D, et al. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol. 2007;47(4):461–470.
   Google Scholar
• Aguilar G, Azanza JR, Carbonell JA, et al. Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2014;69(6):1620–1623.
   Google Scholar
• De Rosa FG, Corcione S, Baietto L, et al. Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH. J Chemother. 2013;25(6):376–378.
   Google Scholar
• Leitner JM, Meyer B, Fuhrmann V, et al. Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration. J Antimicrob Chemother. 2011;66(4):880–884.
   Google Scholar
• Aguilar G, Ferriols R, Carbonell JA, et al. Pharmacokinetics of anidulafungin during venovenous extracorporeal membrane oxygenation. Crit Care. 2016;20(1):325.
   Google Scholar
• Cohen-Wolkowiez M, Benjamin DK Jr., Piper L, et al. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther. 2011 May;89(5):702–707.
   Google Scholar
• Roilides E, Carlesse F, Tawadrous M, et al. Safety, efficacy and pharmacokinetics of anidulafungin in patients 1 month to <2 years of age with invasive Candidiasis, including Candidemia. Pediatr Infect Dis J. 2020 Apr;39(4):305–309.
   Google Scholar
• Kang C-I, Rouse MS, Mandrekar JN, et al. Anidulafungin treatment of candidal central nervous system infection in a murine model. Antimicrob Agents Chemother. 2009;53(8):3576–3578.
   Google Scholar
• Merck & CO., INC. Caspofungin [package insert]. U.S. Food and Drug Administration website; 2005 February [cited 2020 May 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21227s015lbl.pdf
   Google Scholar
• Xellia Pharmaceuticals ApS. Caspofunin [product information]. European Medicines Agency website; 2016 February [cited 2020 May 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/caspofungin-accord-epar-product-information_en.pdf
   Google Scholar
• Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother. 2004 Mar;48(3):815–823.
   Google Scholar
• Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005 Nov;49(11):4536–4545.
   Google Scholar
• Sáez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age [article]. Antimicrob Agents Chemother. 2009;53(3):869–875.
   Google Scholar
• Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics. 2009 Mar;123(3):877–884.
   Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003 Sep 18;349(12):1157–1167.
   Google Scholar
• Long D, Koren G, James A. Ethics of drug studies in infants: how many samples are required for accurate estimation of pharmacokinetic parameters in neonates? J Pediatr. 1987 Dec;111(6 Pt 1):918–921.
   Google Scholar
• European Union. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. Eur J Health Law. 2008 Jul;15(2):223–250.
   Google Scholar